TRiCares, a Paris, France- and Munich, Germany-based company which specializes in the field of minimally invasive treatment of tricuspid regurgitation, raised $50m in Series D funding.
The round was led by a single, strategic investor.
The company intends to use the funds to support upcoming US and EU clinical milestones for its transfemoral tricuspid heart valve replacement system, Topaz.
Led by CEO and President Ahmed Elmouelhi, TRiCares is a dedicated medical device company having the vision of bringing to the market a transfemoral tricuspid valve replacement system (TTVR). This catheter system is inserted via the femoral vein and transports the prosthesis into the right half of the heart, where it is finally released to replace the diseased tricuspid valve. This implantation technique also allows the treatment of severely ill patients.
TRiCares recently secured Investigational Device Exemption (IDE) for an EFS from the United States Food and Drug Administration (FDA). The study will commence in the coming months, with patients to be enrolled at up to 8 potential sites in the United States and Canada, overseen by leading principal investigators Susheel Kodali, MD (NewYork-Presbyterian/Columbia University Irving Medical Center) and Gorav Ailawadi, MD (University of Michigan Health System).
The company previously closed a $55m (€51m) Series C financing round, 415 Capital, Andera Partners, Bayern Kapital, BioMed Partners, Credit Mutuel Innovation, GOCapital, Karista and Wellington Partners.
FinSMEs
25/07/2024